Advertisement

Topics

Search Results for "Avesthagen Limited Cosmosid"

05:38 EDT 27th July 2016 | BioPortfolio

Matching Channels

PATHSEEK

Sequencing platforms in diagnostic laboratories may aid both patient management by detecting resistance associated mutations, and public health measures, by determining phylogenetic relationships be...

India

India, in the Asian subcontinent is the world’s fourth largest producer of pharmaceuticals, and is thought as one of the most promising biotech markets in the world. Several important steps ...

RPL554

Verona’s lead drug, RPL554, is a dual phosphodiesterase (PDE) 3 and 4 inhibitor being developed as a novel treatment for chronic obstructive airways disease as COPD (chronic obstructive pulmon...

Facebook - BioPortfolio Pages

BioPortfolio has launched a number of Facebook pages to allow our visitors to keep track with latest news, published paper and clinical trials by lead biotechnology and healthcare topics:- &nbs...

Coronavirus

Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronavir...

Matching News

CosmosID closes $6mm Series B

Genomics firm CosmosID Inc. raised $6mm in its Series B financing led by the Applied Value Group.

CosmosID Raises $6 Million in Series B Funding

ROCKVILLE, Md., Jan. 27, 2016 /PRNewswire/ -- CosmosID, the leading genomic big data company focused on microbiome research, outbreak investigations, and infectious disease diagnostics, using next-gen...

CosmosID Announces Partnership with QIAGEN for Microbial Analysis

ROCKVILLE, Md., Feb. 3, 2016 /PRNewswire/ -- CosmosID, a leading genomic big data company, today announced a partnership with QIAGEN to launch its metagenomics analysis platform in QIAGEN's CLC Genomi...

CosmosID completes venture financing

Global Microbiome Initiative Explores Subways for Drug-Resistance Markers

Weill Cornell Medicine researchers will use tools and technologies from Qiagen and CosmosID in a global study that the partners said today will collect DNA and RNA samples from high-traffic areas in...

CosmosID and The BioCollective Offer a Whole Genome Shotgun Sequencing Based Comprehensive Microbiome Analysis Kit

ROCKVILLE, Md., June 17, 2016 /PRNewswire/ -- CosmosID and The BioCollective today announced a new Comprehensive Microbiome Analysis Kit for in-depth, high-resolution identification and characterizati...

Global urban microbiome consortium teams up with Qiagen, CosmosID

The Metagenomics and Metadesign of Subways and Urban Biomes consortium, led by Weill Cornell Medicine, is partnering with Qia -More- 

New Agreements Underscore QIAGEN's Leadership in Bioinformatics

HILDEN, Germany and AARHUS, Denmark, February 2, 2016 /PRNewswire/ -- FDA centers and researchers gain access to QIAGEN's enhanced solutions for applications including microbial and microbiome analys...

Matching PubMed Articles

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement